Novo Nordisk confident of amycretin obesity drug launch this decade

Novo Nordisk is very comfortable it will be able to launch the pill version of its experimental weight loss drug amycretin this decade, the drugmaker's head of development told Reuters on Friday, a day after it announced strong early trial data on it.